SCHEMBL3741806

SCHEMBL3741806

c1ccc(/N=N/c2ccc3c(c2)Cc2cc(/N=N/c4ccccc4)ccc2-3)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
CYP1A2 P05177 4/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2C19 P33261 2/20 0.47
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
MAPT P10636 3/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 3/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.45
CD69 Q07108 1/20 0.44
CYP2C9 P11712 2/20 0.43
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SRD5A2 P31213 1/20 0.42
TRPA1 O75762 2/20 0.41
MAPK1 P28482 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3741810 1.00 ALDH1A1 (0.50) ALDH1A1CYP1A2CYP3A4CYP2C19MEN1
SCHEMBL7703270 0.79 SRD5A2 (0.55) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL7703269 0.79 SRD5A2 (0.55) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL2165572 0.79 CYP1A2 (0.55) ALDH1A1CYP1A2CYP3A4CYP2C19MEN1
SCHEMBL18065739 0.77 ALDH1A1 (0.55) ALDH1A1CYP1A2CYP3A4CYP2C19MAPT
SCHEMBL3725837 0.77 MAOA (0.56) ALDH1A1CYP1A2CYP3A4CYP2C19KMT2A
SCHEMBL3725841 0.77 MAOA (0.56) ALDH1A1CYP1A2CYP3A4CYP2C19KMT2A
SCHEMBL2168127 0.75 SMN1; SMN2 (0.57) ALDH1A1CYP1A2CYP3A4CYP2C19MEN1
SCHEMBL21023910 0.74 ALDH1A1 (0.92) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL21024214 0.74 ALDH1A1 (0.92) ALDH1A1MEN1KMT2AMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825279-B2 Fused ring dicationic anti-protozoan agents and their prodrugs THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2010-11-02 US disclosed
EP-1689705-A4 FUSED RING DICATIONIC ANTI-PROTOZOAN AGENTS AND THEIR PRODRUGS UNIV NORTH CAROLINA (US) 2007-08-29 EP disclosed
EP-1689705-A2 FUSED RING DICATIONIC ANTI-PROTOZOAN AGENTS AND THEIR PRODRUGS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2006-08-16 EP disclosed
US-20050165044-A1 Fused ring dicationic anti-protozoan agents and their prodrugs BOYKIN DAVID W (US) 2005-07-28 US disclosed
WO-2005051296-A2 FUSED RING DICATIONIC ANTI-PROTOZOAN AGENTS AND THEIR PRODRUGS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165044-A1 Fused ring dicationic anti-protozoan agents and their prodrugs DHODH, DHFR, PAICS ALDH1A1 4131/4885CYP1A2 342/4885CYP3A4 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.